Somatic

Somatic is a pre-clinical stage biotechnology company focused on developing a proprietary platform for in vivo cell engineering. The company's technology aims to enable the precise modification of cells directly within the human body, potentially overcoming the logistical complexities and high costs associated with traditional ex vivo cell therapies. By leveraging advanced delivery mechanisms and genetic payloads, Somatic seeks to create scalable and accessible genetic medicines for a broad range of therapeutic applications, including genetic disorders and cancer. The company is currently operating in a stealth or early-development phase, supported by prominent venture capital investors.